

The Medical Letter[®]

on Drugs and Therapeutics

COMPARISON CHART: Interleukin (IL) Antagonists and Oral JAK Inhibitors for Moderate to Severe Atopic Dermatitis

Updated February 17, 2026

The Medical Letter[®]

Because the source matters.

To support more content like this, please consider making a [donation](#) or becoming a [subscriber](#).

The Medical Letter is a nonprofit organization* that relies solely on subscription fees and donations to support our mission of providing objective, practical, and timely information on drugs and therapeutics.

Our work relies on support from people like you who value credible, unbiased drug information that is free of any commercial interest.

For more information visit our [website](#) or call Customer Service at: 800-211-2769

*The Medical Letter is a nonprofit, tax-exempt organization under Section 501(C)(3) of the Internal Revenue Code.
Donations are tax-deductible as allowed by law.

INTERLEUKIN (IL) ANTAGONISTS AND ORAL JAK INHIBITORS FOR MODERATE TO SEVERE ATOPIC DERMATITIS

Drug/Formulations	Class	Indication	Efficacy at 16 Weeks ¹	Usual Dosage	Cost ²
Dupilumab – Dupixent (Sanofi/Regeneron) 200 mg/1.14 mL, 300 mg/2 mL prefilled pens, syringes	IL-4 and IL-13 inhibitor	≥6 months old with disease not adequately controlled with topical therapy	With topical steroid (adults): IGA response rate: 39% EASI-75: 69% (package insert)	≥6 yrs and ≥60 kg: 600 mg SC, then 300 mg SC q2 wks 6-17 yrs and 30-59 kg: 400 mg SC, then 200 mg SC q2 wks 6-17 yrs and 15-29 kg: 600 mg SC, then 300 mg SC q4 wks 6 mos-5 yrs and 15-29 kg: 300 mg SC q4 wks 6 mos-5 yrs and 5-14 kg: 200 mg SC q4 wks	\$12,579
Lebrikizumab – Ebglyss (Lilly) 250 mg/2 mL prefilled pens, syringes	IL-13 antagonist	≥12 years old (and ≥40 kg) with disease not adequately controlled with topical therapy	With topical steroid: IGA response rate: 41% EASI-75: 70% (JAMA Dermatol 2023; 159:182)	≥12 yrs: 500 mg SC at wks 0 and 2, then 250 mg SC q2 wks (250 mg SC q4 wks if adequate response at wk 16)	21,000
Tralokinumab – Adbry (Leo) 150 mg/1 mL prefilled syringes; 300 mg/2 mL auto-injectors	IL-13 antagonist	≥12 years old with disease not adequately controlled with topical therapy	With topical steroid: IGA response rate: 39% EASI-75: 56% (Br J Dermatol 2021; 184:450)	12-17 yrs: 300 mg SC wk 0, then 150 mg SC q2 wks ≥18 yrs: 600 mg SC wk 0, then 300 mg SC q2 wks (300 mg SC q4 wks if <100 kg and clear/almost clear skin at wk 16)	12,208
Nemolizumab – Nemluvio (Galderma) 30 mg/mL prefilled pens	IL-31 antagonist	≥12 years old with disease not adequately controlled with topical therapy	With topical steroid +/- calcineurin inhibitor: IGA response rate: 36-38% EASI-75: 59% (Lancet 2024; 404:445)	≥12 yrs: 60 mg SC at wk 0, then 30 mg SC q4 wks (30 mg SC q8 wks if clear/almost clear skin at wk 16)	13,356
Abrocitinib – Cibinqo (Pfizer) 50, 100, 200 mg tabs	JAK Inhibitor	≥12 years old with disease not controlled with other systemic drugs	100 mg/day with topical therapy: IGA response rate: 37% EASI-75: 56% (NEJM 2021; 384:1101)	≥12 yrs: 100 mg PO once/day (200 mg once/day can be considered if adequate response not achieved)	18,501
Upadacitinib – Rinvoq (Abbvie) 15, 30 mg ER tabs	JAK Inhibitor	≥12 years old with disease not controlled with other systemic drugs	15 mg/day with topical therapy: IGA response rate: 40% EASI-75: 65% (Lancet 2021; 397:2169)	≥12 yrs and ≥40 kg: 15 mg PO once/day (30 mg once/day can be considered if <65 yrs and adequate response not achieved)	21,271

1. IGA response rate = an improvement in the score on the clinician-rated Investigator's Global Assessment (IGA) scale from 3 to 4 (signifying moderate or severe disease) at baseline to 0 or 1 (signifying clear or almost clear skin). EASI-75 = ≥75% improvement in the Eczema Area and Severity Index (EASI) score.

2. Approximate WAC for 3 months' treatment at the lowest usual adult dosage. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. February 5, 2026. Reprinted with permission by First Databank, Inc. All rights reserved. ©2026. www.fdbhealth.com/policies/drug-pricing-policy.